Kedrion Biopharma Recognized for Innovation in Treating Rare Disease

The award was presented Sunday at NORD's Rare Impact Awards at the Rock & Roll Hall of Fame in Cleveland, Ohio. Rebecca Bialas, President of the Plasminogen Deficiency Foundation, presented the award to Giorgio Masetti-Zannini, VP, US Regional Commercial Director of Kedrion Biopharma, who accepted the award on behalf of Kedrion Biopharma. "We thank NORD for this honor and for all the important work they do to support those who suffer from rare diseases and conditions, said Masetti-Zannini. I'd also like to give special recognition to our colleagues at Prometic in Laval, Canada, whose creativity, hard work, and persistence ultimately resulted in this treatment."

Paolo Marcucci, Executive Chairman of Kedrion, said he was pleased by the recognition "From our inception, we have been dedicated to the mission of providing relief to people suffering from rare diseases. Our generous donors offer us the profound opportunity to develop life-changing therapies. We embarked on the specific quest to develop a treatment for Plasminogen deficiency some fifteen years ago; today we accept this award with great pride".

Rebecca Bialas, the mother of a child with PLGD-1, said "I'm so thankful the folks at Kedrion have taken up this cause and are doing all the wonderful things they're doing. I can't put into words how thankful I am that this is happening. This treatment has given us hope that we can move forward with a future for our children and other patients with this disorder." 

Logo: https://mma.prnewswire.com/media/1736227/Kedrion_Biopharma_Logo.jpg